Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for ixazomib root_codes_MANUFACTURER\ PRODUCT\ INFORMATION in MANUFACTURER PRODUCT INFORMATION (approximate match)

Showing 1 - 1 of 1 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ZOTIRACICLIB CITRATE

3VF50SU4RZ

Search for Structure

Status:

Investigational

Source:

NCT01699152: Phase 1 Interventional Completed Chronic Lymphocytic Leukemia

(2012)

Source URL:

https://clinicaltrials.gov/ct2/show/NCT01699152

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase receptor FLT3

Cyclin-dependent kinase 2/cyclin A

Tyrosine-protein kinase JAK2

Structure of ZOTIRACICLIB CITRATE

ACHIRAL

ZOTIRACICLIB CITRATE

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1